CN113186276A - Marker for coronary heart disease and treatment drug thereof - Google Patents
Marker for coronary heart disease and treatment drug thereof Download PDFInfo
- Publication number
- CN113186276A CN113186276A CN202110685597.8A CN202110685597A CN113186276A CN 113186276 A CN113186276 A CN 113186276A CN 202110685597 A CN202110685597 A CN 202110685597A CN 113186276 A CN113186276 A CN 113186276A
- Authority
- CN
- China
- Prior art keywords
- coding rna
- seq
- long
- heart disease
- coronary heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
The invention provides a marker for coronary heart disease and a medicament for treating the coronary heart disease, and belongs to the technical field of cardiovascular diseases. The marker provided by the invention is long non-coding RNA NONHSAG020448.2, and the sequence of the long non-coding RNA is shown as SEQ ID NO. 1. The invention has the beneficial effects that the long-chain non-coding RNA NONHSAG020448.2 provided by the invention can be used as a marker for coronary heart disease diagnosis, and early diagnosis and early treatment of coronary heart disease are realized. Moreover, the invention discovers that the inhibition of the long-chain non-coding RNA NONHSAG020448.2 can effectively improve the activity of HUVEC cells under hypoxia simulation conditions, so that the inhibitor for inhibiting the expression of the long-chain non-coding RNA NONHSAG020448.2 can be used for preparing the medicine for treating coronary heart disease.
Description
Technical Field
The invention belongs to the technical field of cardiovascular diseases, and particularly relates to a marker for coronary heart disease and a therapeutic drug thereof.
Background
With the increasing aging of the population, the death rate of cardiovascular diseases is rapidly increased, which not only brings great pain to patients, but also causes heavy social burden. Among cardiovascular diseases, coronary heart disease is one of the most common diseases. Coronary heart disease is collectively referred to as coronary atherosclerotic heart disease (CAD), which is a heart disease caused by myocardial ischemia, hypoxia or necrosis due to stenosis or blockage of the lumen caused primarily by atherosclerotic lesions in the coronary arteries. Despite the great advances in the recent years in the diagnosis and treatment of coronary heart disease, coronary heart disease remains a leading cause of death in the global population.
At present, the clinical diagnostic means for coronary heart disease are still few, and at present, invasive blood drawing is mainly used for detecting plasma biochemical markers such as cardiac myozyme, troponin and the like and non-invasive conventional electrocardiograms, but the diagnostic means only have diagnostic significance after clinical symptoms such as angina pectoris, angiostenosis, insufficient blood supply and the like appear. Therefore, the accurate diagnosis of coronary heart disease is of great significance for effectively treating coronary heart disease.
Disclosure of Invention
The invention aims to provide a marker capable of effectively diagnosing coronary heart disease aiming at a coronary heart disease diagnosis marker which is lack of high specificity and high sensitivity clinically.
In order to achieve the purpose, the technical scheme provided by the invention is as follows: application of a reagent for detecting expression quantity of long non-coding RNA NONHSAG020448.2 in preparation of a coronary heart disease detection product is characterized in that the sequence of the long non-coding RNA NONHSAG020448.2 is shown as SEQ ID No. 1.
Preferably, the product comprises a chip, a kit, or a high throughput sequencing platform.
Preferably, the reagent is a PCR primer for detecting the expression level of the long non-coding RNA NONHSAG 020448.2.
Preferably, the sequences of the PCR primers are shown as SEQ ID NO.2 and SEQ ID NO. 3.
Secondly, the invention provides the following technical scheme: the application of the PCR primer for amplifying the long non-coding RNA NONHSAG020448.2 in the preparation of a coronary heart disease kit is disclosed, and the sequence of the primer is shown as SEQ ID NO.2 and SEQ ID NO. 3.
Furthermore, the invention provides application of a preparation for inhibiting expression of long-chain non-coding RNA NONHSAG020448.2 in preparation of a coronary heart disease treatment drug.
Preferably, the sequence of the long non-coding RNA NONHSAG020448.2 is shown as SEQ ID NO. 1.
Preferably, the preparation is siRNA for inhibiting the expression of long non-coding RNA NONHSAG020448.2, and the sequence of the siRNA is shown as SEQ ID NO.6 and SEQ ID NO. 7.
Finally, the invention provides the following technical scheme: application of an agent for inhibiting expression of long-chain non-coding RNA NONHSAG020448.2 in preparation of HUVEC cell activity promoter in anoxic environment.
Preferably, the sequence of the long non-coding RNA NONHSAG020448.2 is shown as SEQ ID NO. 1; the preparation is siRNA for inhibiting expression of long-chain non-coding RNA NONHSAG020448.2, and the sequences of the siRNA are shown as SEQ ID NO.6 and SEQ ID NO. 7.
The invention has the beneficial effects that:
the long-chain non-coding RNA NONHSAG020448.2 provided by the invention can be used as a marker for coronary heart disease diagnosis, and realizes early diagnosis and early treatment of coronary heart disease. Moreover, the invention discovers that the inhibition of the long-chain non-coding RNA NONHSAG020448.2 can effectively improve the activity of HUVEC cells under hypoxia simulation conditions, so that the inhibitor expressed by the long-chain non-coding RNA NONHSAG020448.2 can be used for preparing the medicine for treating coronary heart disease.
Drawings
FIG. 1 shows the expression of long non-coding RNA NONHSAG020448.2 in the plasma of patients with coronary heart disease and normal human plasma;
FIG. 2 is a ROC curve of long non-coding RNA NONHSAG020448.2 as the difference between plasma of coronary heart disease patients and normal human plasma;
FIG. 3 shows the expression of long non-coding RNA NONHSAG020448.2 in normoxic and hypoxic cultured HUVEC cells;
FIG. 4 shows the inhibitory effect of siRNA of long non-coding RNA NONHSAG 020448.2;
FIG. 5 shows the results of MTT assay;
FIG. 6 shows the detection results of Western blotting.
Detailed Description
In order to clearly illustrate the technical features of the present solution, the present solution is explained below by way of specific embodiments.
Example 1
Study object
(1) Plasma 42 cases of patients with Coronary Artery Disease (CAD) and plasma 40 cases of healthy persons were collected from a hospital affiliated with the corning medical school under coronary angiography from 2020 1 to 2020 10.
(2) Inclusion criteria were: the inclusion standard of the coronary artery patients is that the patients with 1 or more coronary artery angiostenosis degree more than or equal to 50 percent are confirmed after coronary angiography;
(3) exclusion criteria: (1) hematological diseases, known bleeding or coagulation disorders; or patients with a history of cerebral hemorrhage or subarachnoid hemorrhage, cerebral apoplexy; (2) patients with chronic obstructive pulmonary disease, congenital heart disease, valvular heart disease, and cardiac arrhythmias; (3) patients with peripheral vascular disease, i.e. autoimmune disease; (4) patients with acute infections or inflammatory diseases; (5) patients with acute or chronic renal insufficiency and liver function impairment; (6) hematological disorders, such as patients with a history of cerebral hemorrhage or subarachnoid hemorrhage or a history of cerebral stroke.
Example 2
Plasma sample acquisition
(1) Collecting 5ml of fasting peripheral venous blood of the selected patient in the early morning, placing in a centrifuge, centrifuging for 3000min, and centrifuging for 10 min;
(2) the supernatant serum was aspirated, dispensed into RNase-free EP tubes (200 ul), and placed in a freezer at-80 ℃ for use.
Example 3
RNA extraction
(1) Adding 1ml of RNA extracting solution into an EP tube containing serum, lightly shaking, and uniformly blowing by using a pipette gun;
(2) adding 200ul of chloroform, mixing, and standing at room temperature for 5 min;
(3) placing the EP tube into a centrifuge, and centrifuging at 12000rpm at 4 ℃ for 10 min;
(4) taking out the EP tube, transferring the supernatant to a new EP tube, adding isopropanol with the same volume, fully mixing, and standing at room temperature for 10 min;
(5) placing in a centrifuge, centrifuging at 4 deg.C 12000rpm for 10min, removing supernatant, adding 75% ethanol, washing for 2 times, placing in the centrifuge again, and centrifuging at 4 deg.C 8000rpm for 5 min;
(6) the supernatant was removed, air dried, 30ul DEPC water was added, and the RNA concentrations of each group were determined using an ultraviolet spectrophotometer and stored at-80 ℃.
Example 4
cDNA Synthesis
1. Residual genomic DNA removal
Prepare the following mixture in RNase free centrifuge tube, gently blow and mix with a pipette. Incubate at 42 ℃ for 2 min.
2. Preparation of reverse transcription reaction system
4 XHiFair III Supermix plus pieces are added into the pulp in the reaction tube in the step 1, and lightly blown by a pipettor to be mixed evenly.
3. Reverse transcription reaction
Example 5
Real-time fluorescent quantitative RT-PCR detection of relative expression of long non-coding RNA NONHSAG020448.2
(1) Design primers for long non-coding RNA NONHSAG020448.2, SEQ ID NO.1 and β -actin:
the primer sequence of the long non-coding RNA NONHSAG020448.2 is as follows:
an upstream primer: 5'-CAGGAAGGGAAAGAGAGGCG-3' (SEQ ID NO. 2)
A downstream primer: 5'-GCCAGTCGTCATGGAGAGTG-3' (SEQ ID NO. 3)
The primer sequence of beta-actin is as follows:
an upstream primer: 5'-CGTGGACATCCGCAAAGAC-3' (SEQ ID NO. 4)
Downstream primer 5'-CTGCTGTCACCTTCACCGTTC-3' (SEQ ID NO. 5)
(2) The following reaction system was prepared on ice: h2O
(3) Real-time fluorescent quantitative RT-PCR reaction
(4) By using 2-△△CtMethod for processing real-time quantitative PCR data
The expression difference of the long-chain non-coding RNA NONHSAG020448.2 in the control group and the coronary heart disease group is shown in FIG. 1, the relative expression amount of the long-chain non-coding RNA NONHSAG020448.2 in the coronary heart disease group is 2.529 +/-1.006, and P is less than 0.0001.
The result shows that the expression level of the long-chain non-coding RNA NONHSAG020448.2 in the plasma of the coronary heart disease patient is obviously higher than that in the plasma of the normal human of a control group.
Example 6 detection of Long non-coding RNA NONHSAG020448. sensitivity and specificity as marker
(1) A ROC curve was plotted for the difference in expression of the long non-coding RNA NONHSAG020448.2 between the control group and the coronary heart disease group, and the ROC curve was shown in FIG. 2.
The results of ROC are shown below:
the area under the curve was 0.896, the confidence interval was 0.830-0.961, the sensitivity was 0.714, and the specificity was 0.968.
The above results indicate that long non-coding RNA NONHSAG020448.2 has excellent diagnostic value when used as a predictor variable for control and coronary heart disease.
Example 7
Hypoxia-treated human umbilical vein vascular endothelial cells HUVEC were examined for differences in expression of the long non-coding RNA NONHSAG 020448.2.
(1) Inoculating HUVEC cells into a cell culture dish, adding an ECM complete culture medium, adding an ECM basic culture medium when the cell density reaches 70-80%, and starving for 12h at 37 ℃;
(2) endothelial cells were placed in an anoxic cell incubator (1% O)2) After culturing for 48h, extracting RNA to detect the expression of the long-chain non-coding RNA NONHSAG 020448.2.
The results of the experiment are shown in FIG. 3, wherein the relative expression amount of the long non-coding RNA NONHSAG020448.2 in the hypoxia group is 9.730 +/-1.549, and P = 0.0006.
The result shows that when HUVEC is damaged by hypoxia, the relative expression of long-chain non-coding RNA NONHSAG020448.2 is obviously increased, and the result is consistent with the data of clinical detection.
Example 8
Design and detection of siRNA of long non-coding RNA NONHSAG020448.2
1. The sequence of the siRNA of the long non-coding RNA NONHSAG020448.2 provided by the invention is as follows:
sense strand: 5'-UCUAAUUACUGCAGAAUGG-3', (SEQ ID NO. 6);
antisense strand: 5'-CCAUUCUGCAGUAAUUAGA-3', (SEQ ID NO. 7);
2. HUVECs were seeded in cell culture plates, transfected with siRNA and NC, while untreated groups were used as controls, and 48h after transfection, RNA was extracted and the relative expression of NONHSAG020448.2, a long non-coding RNA, was examined.
The experimental result is shown in FIG. 4, the inhibition rate of siRNA is 81.1%, and P = 0.0002, therefore, the siRNA provided by the invention can effectively inhibit the expression of long non-coding RNA NONHSAG 020448.2.
Example 9
Detecting the Effect of siRNA on the cellular Activity of HUVEC cells in hypoxic Environment
(1) The experiment was divided into three groups, each of which was a blank control group: untransfected 1X 10 cells5HUVEC cells of (1)Culturing in normal oxygen condition for 48 hr; NC group: 1X 10 of the transfected NC5The HUVEC cells are put into an anoxic cell incubator to be cultured for 48 hours; experimental groups: 1X 10 to be transfected with siRNA5The HUVEC cells are put into an anoxic cell incubator to be cultured for 48 hours;
(2) adding MTT to detect the absorbance at 490nm after the culture is finished;
the absorbance difference between the different experimental groups is shown in fig. 5, wherein the absorbance of the blank control group is 0.617 ± 0.016, the absorbance of the NC group is 0.328 ± 0.025, the absorbance of the experimental group is 0.449 ± 0.024, and the P value between the NC group and the experimental group is 0.0037, and the difference has statistical significance.
It is demonstrated that the siRNA of the present invention can effectively improve the activity of HUVEC cells after inhibiting the expression of long non-coding RNA NONHSAG 020448.2.
Example 10
Western blotting method for detecting protein expression level of cleared Caspase3
(1) HUVEC cells were seeded in 6-well culture plates, when the cell density reached 80% more, the blank control group was left untreated, NC group was transfected with si-NC, experimental group was transfected with siRNA, and after 6 hours of transfection, NC group and experimental group were placed in 1% O2The incubator of (1);
(2) after culturing for 48h, adding 100 mu L of PIPA lysate into each hole, scraping the cells by using a cell scraper after the cells are fully lysed, and collecting the cells into a centrifuge tube;
(3) standing on ice for 30min to completely lyse cells;
(4) centrifuging at 4 ℃ and 12000rpm for 20 minutes, sucking supernatant, detecting protein concentration by using a BCA method, adjusting the protein concentration to 2 mug/ml, and boiling in boiling water for 5 minutes to obtain a protein sample;
(5) preparing 12% SDS-PAGR glue, adding 10 mul protein sample into each hole, and adding protein Marker;
(6) performing constant-voltage 90V electrophoresis, and adjusting the voltage to 120V when an electrophoresis strip runs out of the concentrated gel until bromophenol blue reaches the bottom of the separation gel;
(7) placing a membrane rotating clamp according to a model of sponge-filter paper-separation gel-membrane-filter paper-sponge, and rotating for 1.5h under 250mA electricity;
(8) after the electrotransformation is finished, taking out the membrane, putting the membrane into 5% of skimmed milk powder, and sealing the shaking table for 1 h;
(9) incubating cleaned Caspase3 and GAPDH primary antibody, and sealing the shaking table at 4 ℃ overnight;
(10) adding TBST for washing membrane, 3 times each time for 10min, incubating secondary antibody, and incubating for 1h in a shaking table at room temperature;
(11) TBST was added thereto to wash the film for 10min 3 times, and after washing, exposure was carried out to obtain the results shown in FIG. 6.
As can be seen from the figure, hypoxia can increase the expression level of the cleared Caspase3 protein in the HUVEC cells, and the expression level of the cleared Caspase3 protein can be reduced to a certain extent after siRNA transfection.
It is demonstrated that the siRNA of the present invention can increase the activity of HUVEC cells by reducing the apoptosis of HUVEC cells after inhibiting the expression of long non-coding RNA NONHSAG 020448.2.
Sequence listing
<110> Guo dao channel
<120> marker for coronary heart disease and therapeutic drug thereof
<130> 2021.6.18
<160> 7
<170> SIPOSequenceListing 1.0
<210> 1
<211> 340
<212> DNA
<213> Human source (Human)
<400> 1
cctcagctcc acggggagct cttggacgct ccgcagcgct ttcgcagagt ccccagttct 60
cccgtcccgc cgggactcca ggaagggaaa gagaggcgtg gaattggcag agccctggca 120
gcgtgatgag gaaacagacc ccattctgca gtaattagaa aacgtcatga tacaatgcca 180
cgtgaagcac acaccagcac ctggcaaaac gctcaacctg gatcaaatta ctgggaaaca 240
tcagatgggt ccagattacg caggacactc tccatgacga ctggcctgga atcctcaaaa 300
acagcaatgc tgtgaaagac ataaataaaa cagaaaaaaa 340
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
caggaaggga aagagaggcg 20
<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
gccagtcgtc atggagagtg 20
<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
cgtggacatc cgcaaagac 19
<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ctgctgtcac cttcaccgtt c 21
<210> 6
<211> 19
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
ucuaauuacu gcagaaugg 19
<210> 7
<211> 19
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
ccauucugca guaauuaga 19
Claims (10)
1. Application of a reagent for detecting expression quantity of long non-coding RNA NONHSAG020448.2 in preparation of a coronary heart disease detection product is characterized in that the sequence of the long non-coding RNA NONHSAG020448.2 is shown as SEQ ID No. 1.
2. The use of claim 1, wherein the product comprises a chip, a kit, or a high throughput sequencing platform.
3. The use of claim 1, wherein the reagent is a PCR primer for detecting the expression level of long non-coding RNA NONHSAG 020448.2.
4. The use according to claim 3, wherein the PCR primers have the sequences shown in SEQ ID No.2 and SEQ ID No. 3.
5. The application of the PCR primer for amplifying the long non-coding RNA NONHSAG020448.2 in the preparation of the coronary heart disease kit is characterized in that the sequence of the primer is shown as SEQ ID NO.2 and SEQ ID NO. 3.
6. The application of the preparation for inhibiting the expression of long-chain non-coding RNA NONHSAG020448.2 in preparing a medicament for treating coronary heart disease.
7. The use according to claim 6, wherein the long non-coding RNA NONHSAG020448.2 has the sequence shown in SEQ ID No. 1.
8. The use according to claim 6, wherein the agent is siRNA inhibiting expression of long non-coding RNA NONHSAG020448.2, the siRNA having the sequence as shown in SEQ ID No.6 and SEQ ID No. 7.
9. Application of an agent for inhibiting expression of long-chain non-coding RNA NONHSAG020448.2 in preparation of HUVEC cell activity promoter in anoxic environment.
10. The use according to claim 9, wherein the long non-coding RNA noshsag 020448.2 has the sequence shown in SEQ ID No. 1; the preparation is siRNA for inhibiting expression of long-chain non-coding RNA NONHSAG020448.2, and the sequences of the siRNA are shown as SEQ ID NO.6 and SEQ ID NO. 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110685597.8A CN113186276A (en) | 2021-06-21 | 2021-06-21 | Marker for coronary heart disease and treatment drug thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110685597.8A CN113186276A (en) | 2021-06-21 | 2021-06-21 | Marker for coronary heart disease and treatment drug thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113186276A true CN113186276A (en) | 2021-07-30 |
Family
ID=76976574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110685597.8A Withdrawn CN113186276A (en) | 2021-06-21 | 2021-06-21 | Marker for coronary heart disease and treatment drug thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113186276A (en) |
-
2021
- 2021-06-21 CN CN202110685597.8A patent/CN113186276A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107385035B (en) | Serum/plasma miRNA marker related to type 2 diabetes retinopathy and application thereof | |
| CN108179194B (en) | Tumor molecular marker circBIRC6, and inhibitor and application thereof | |
| CN112011620B (en) | Application of circ-SLC38A1 as target in medicine for inhibiting bladder cancer cells | |
| CN111286536B (en) | Gene marker for diagnosing myocardial infarction and application thereof | |
| CN112126686B (en) | Early-stage screening molecular marker for renal fibrosis and application thereof | |
| CN111118146B (en) | Application of LncRNA in diagnosis of breast cancer chemotherapy-related myocardial injury patient | |
| CN109097358B (en) | Application of lncRNA in prevention or treatment of hypertension | |
| CN113186276A (en) | Marker for coronary heart disease and treatment drug thereof | |
| CN111154863B (en) | Application of lncRNA in preparation of product for diagnosing and/or treating osteoarthritis | |
| CN111118143B (en) | Reagent for detecting and targeting RP11-754B17.1 and application thereof in arthritis | |
| CN112852950B (en) | Acute myocardial infarction biomarker and application thereof | |
| CN114934115A (en) | Application of GMFB protein as biological marker of renal clear cell carcinoma | |
| CN113881674A (en) | Application of LINC00958 in preparation of reagent and kit for diagnosing and monitoring chronic myelocytic leukemia | |
| CN107151695B (en) | PiRNA combination for detecting acute myocardial ischemia diseases and detection method and application thereof | |
| CN112813158B (en) | MiRNA marker related to myocardial fibrosis disease auxiliary diagnosis and application thereof | |
| CN111235263B (en) | Target gene for diagnosis and treatment of osteoarthritis | |
| CN114272257B (en) | Application of miR-204-5p mimics or miR-204-3p mimics in preparation of drugs for treating atherosclerosis | |
| CN112795644B (en) | Application of miRNA biomarker in diagnosis of myocardial fibrosis diseases | |
| CN112266954B (en) | Application of miR-125b-2-3p in renal fibrosis | |
| CN111118139B (en) | Molecular target for osteoporosis and application thereof | |
| CN114807348B (en) | Application of long-chain non-coding RNA LRA-1 and interfering RNA thereof in treatment of atherosclerosis | |
| CN111254200B (en) | New application of Gal3st3 gene | |
| CN116254340A (en) | Thoracic aortic aneurysm biomarker and application thereof | |
| CN115466783A (en) | Application of LncTAF15:1-1 in diagnosis and treatment of systemic lupus erythematosus | |
| CN117045671A (en) | Application of miR-4670-3p mimic in preparation of lung cancer treatment drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210730 |
|
| WW01 | Invention patent application withdrawn after publication |